trending Market Intelligence /marketintelligence/en/news-insights/trending/ZOUNjXT7gBoa0PPkcUngqA2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

Proteon Therapeutics closes $22M preferred stock placement

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective

Blog

Corporate Credit Risk Trends in Developing Markets: A Probability of Default Perspective


Proteon Therapeutics closes $22M preferred stock placement

Proteon Therapeutics Inc. closed a private placement of 22,000 of its series A convertible preferred stock, for gross proceeds of $22 million.

The company sold the preferred stock to a syndicate of existing and new investors led by Deerfield Management. Abingworth, Fairmount Funds, Intersouth Partners, Perceptive Advisors, Pharmstandard, RA Capital, Skyline Ventures and TVM Capital also participated in the transaction.

The 22,000 shares of preferred stock are convertible to 22,112,775 common shares, equivalent to an initial conversion price of 99.49 cents apiece.

Proteon Therapeutics plans to use proceeds to complete its ongoing Patency-2 trial and fund continued market access activities. The financing also extends the company's cash runway to the fourth quarter of 2019.

Additionally, Deerfield Management partner Jonathan Leff joined Proteon Therapeutics' board as the preferred stockholders' designee.